InfertilityNCT07556601
Ultra-rapid Blastocyst Vitrification: Pilot Randomized Study
A study testing Standard Vitrification and Ultra-Rapid Vitrification in people with Infertility, run by Fundacion Dexeus at 2 sites in Spain.
Trial summary
Blastocyst vitrification is standard in assisted reproduction, but clinical data on ultra-rapid vitrification are limited. This pilot study evaluates the safety, feasibility, and preliminary clinical performance of an ultra-rapid blastocyst vitrification protocol compared with the standard approach. Read more about this study
- Who is it for?
- Ages 18 to 50 years, women only
- Conditions the study is for
- Infertility
- What is being tested?
- Standard Vitrification and Ultra-Rapid Vitrification
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 2 sitesSpain
- Study dates
- 1 Jun 2026to Mar 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Recipients of donor oocytes
- Blastocysts suitable for cryopreservation
Who cannot join
- Cycles involving PGT
- Cycles not reaching blastocyst stage.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Spain2 sites, 2 recruiting
- Not yet recruiting
Hospital Universitario Quiron Dexeus
Barcelona, 08028
Monica Parriego, PhD, 0034932274700, monpar@dexeus.com
Ignacio Rodriguez, MSc, 0034932274700, nacrod@dexeus.com
- Recruiting
Hospital Universitario Quiron Dexeus
Barcelona, 08028
Ignacio Rodríguez, MSc, 0034932274700, nacrod@dexeus.com
About this study
Official title: Clinical Validation of Ultra-rapid Blastocyst Vitrification: a Randomized Pilot Study in Oocyte Donation Cycles
Blastocyst vitrification is standard in assisted reproduction, but clinical data on ultra-rapid vitrification are limited. This pilot study evaluates the safety, feasibility, and preliminary clinical performance of an ultra-rapid blastocyst vitrification protocol compared with the standard approach.
Read the detailed description
Blastocyst cryopreservation by vitrification is currently the standard approach in assisted reproductive technology, providing high post-warming survival rates and clinical outcomes comparable to those of fresh embryo transfer. Ongoing refinements of vitrification techniques aim to further improve laboratory efficiency and workflow while maintaining biological safety and clinical effectiveness.
Ultra-rapid vitrification protocols have been developed to shorten equilibration times by modifying exposure kinetics to cryoprotectants, while preserving the fundamental biophysical principles of vitrification. Although ultra-rapid warming protocols are well established, clinical data specifically evaluating ultra-rapid vitrification of blastocysts remain limited.
Moreover, ultra-rapid vitrification requires mechanical collapse of the blastocyst before cooling, introducing an additional embryological manipulation with potential biological implications that warrant careful clinical validation. In this context, the present pilot study aims to evaluate the safety, feasibility, and preliminary clinical performance of ultra-rapid blastocyst vitrification compared with the standard vitrification protocol, prior to broader clinical implementation.
- Conditions
- Infertility
- Being tested
- Standard Vitrification, Ultra-Rapid Vitrification
- Medical subject headings
- Infertility
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Standard VitrificationOther
- Equilibration step: Blastocysts are equilibrated in Equilibration Solution (ES) for 10-12 minutes at room temperature.
- Vitrification solution exposure: Blastocysts are then transferred to Vitrification Solution (VS) for a maximum exposure time of 90 seconds.
- Loading: The blastocyst is loaded onto a Cryotop device (Kitazato).
- Vitrification: The Cryotop is plunged directly into liquid nitrogen within 1 second of loading to ensure ultra-rapid cooling.
- Capping: The Cryotop is immediately capped under liquid nitrogen conditions.
Ultra-Rapid VitrificationOther
The ultra-rapid vitrification protocol is identical to the standard protocol in terms of media, devices, and laboratory conditions, with the following modifications:
Preparation step - Blastocyst shrinkage: Prior to equilibration, artificial collapse of the blastocyst is performed using a single laser pulse to induce blastocoel shrinkage.
The subsequent steps are:
- Equilibration step: Blastocysts are equilibrated in Equilibration Solution (ES) for 2-4 minutes.
- Vitrification solution exposure: Transfer to Vitrification Solution (VS) for a maximum of 90 seconds.
- Loading: Loading of the blastocyst onto a Cryotop device.
- Vitrification: Immediate plunging of the Cryotop into liquid nitrogen within 1 second.
- Capping: Immediate capping under liquid nitrogen.
| Study group | Role | What they receive |
|---|---|---|
| Standard Vitrification Protocol | Active comparator | The standard vitrification protocol corresponds to the routine clinical practice of the laboratory and consists of the following steps:
1. Equilibration step: Blastocysts are equilibrated in Equilibration Solution (ES) for 10-12 minutes at room temperature.
2. Vitrification solution exposure: Blastocysts are then transferred to Vitrification Solution (VS) for a maximum exposure time of 90 seconds.
3. Loading: The blastocyst is loaded onto a Cryotop device (Kitazato).
4. Vitrification: The Cryotop is plunged directly into liquid nitrogen within 1 second of loading to ensure ultra-rapid cooling.
5. Capping: The Cryotop is immediately capped under liquid nitrogen conditions. Receives: Other: Standard Vitrification |
| Ultra-Rapid Vitrification Protocol | Experimental | The ultra-rapid vitrification protocol is identical to the standard protocol in terms of media, devices, and laboratory conditions, with the following modifications:
Preparation step - Blastocyst shrinkage: Prior to equilibration, artificial collapse of the blastocyst is performed using a single laser pulse to induce blastocoel shrinkage.
The subsequent steps are:
1. Equilibration step: Blastocysts are equilibrated in Equilibration Solution (ES) for 2-4 minutes.
Vitrification solution exposure: Transfer to Vitrification Solution (VS) for a maximum of 90 seconds.
3. Loading: Loading of the blastocyst onto a Cryotop device. 4. Vitrification: Immediate plunging of the Cryotop into liquid nitrogen within 1 second.
5. Capping: Immediate capping under liquid nitrogen. Receives: Other: Ultra-Rapid Vitrification |
What is being measured
The primary outcome is the main question the study is designed to answer.
Post-warming survival rate
the proportion of vitrified blastocysts that remain morphologically viable after warming, expressed as a percentage of all warmed blastocysts.
Measured: Immediately after warming (within the same laboratory session)
Clinical pregnancy rate per transfer (only first transfer will be considered).
defined as the proportion of embryo transfers resulting in a clinical pregnancy, confirmed by the presence of an intrauterine gestational sac on ultrasound. Only the first embryo transfer per patient is included in the analysis.
Measured: 6-8 weeks after embryo transfer
Secondary outcomes (4)
Blastocyst re-expansion
defined as the resumption of blastocoel expansion after warming, as assessed by partial or complete reformation of the blastocyst cavity, indicating post-warming viability
Measured: Within 2 hours after warming
Post-warming blastocyst morphokinetic parameters
Assessment of post-warming embryo developmental dynamics based on time-lapse observation. Morphokinetic parameters will include time to blastocoel re-expansion and time to resumption of blastocyst development, measured in hours from warming to embryo transfer.
Measured: From embryo warming until embryo transfer (within 2-6 hours post-warming)
Post-warming blastocyst morphological quality
Evaluation of blastocyst morphological quality after warming and prior to embryo transfer. Blastocysts will be graded according to standard morphological criteria based on blastocoel expansion, inner cell mass quality, and trophectoderm appearance. Results will be reported as the proportion of embryos achieving good-quality blastocyst grade per standard scoring system.
Measured: From embryo warming until embryo transfer (within 2-6 hours post-warming)
Technical or embryological adverse events.
defined as any unexpected or unfavorable technical or laboratory-related events occurring during blastocyst warming, handling, culture, or preparation for transfer, including damage to the embryo, procedural errors, or protocol deviations that may affect embryo viability.
Measured: From blastocyst warming until embryo transfer, within the same clinical procedure (up to 6 hours post-warming)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2026
- Study start1 Jun 2026
- Primary completionDec 2027 (estimated)
- Study completionMar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (11)Papers the sponsor has linked to this study.
- Other trials for InfertilityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fundacion Dexeus
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07556601
- Sponsor's protocol ID
- FSD-UFV-2026-04
- Status last verified
- Jun 2026
- First submitted
- 13 Apr 2026
- Last updated
- 30 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Boyard J, Reignier A, Chtourou S, Lefebvre T, Barriere P, Freour T. Should artificial shrinkage be performed prior to blastocyst vitrification? A systematic review of the literature and meta-analysis. Hum Fertil (Camb). 2022 Feb;25(1):24-32. doi: 10.1080/14647273.2019.1701205. Epub 2020 Jan 24.
PubMed 31973647George JS, Keefe KW. Freezer burn or learning curve? Prolonged time since blastocyst vitrification and impact on pregnancy outcomes. Fertil Steril. 2023 Jan;119(1):45-46. doi: 10.1016/j.fertnstert.2022.11.017. Epub 2022 Nov 19. No abstract available.
PubMed 36410446Gunst J, Joris H, Vynck M, Godderis K, Vercammen M, Roggeman S, van de Vijver A. Validation and clinical study of single-step vitrification combined with single-step warming of human blastocysts. J Assist Reprod Genet. 2026 Mar;43(3):837-850. doi: 10.1007/s10815-025-03790-1. Epub 2026 Feb 13.
PubMed 41686351Kovacic B, Taborin M, Vlaisavljevic V, Reljic M, Knez J. To collapse or not to collapse blastocysts before vitrification? A matched case-control study on single vitrified-warmed blastocyst transfers. Reprod Biomed Online. 2022 Oct;45(4):669-678. doi: 10.1016/j.rbmo.2022.03.030. Epub 2022 Apr 10.
PubMed 35963753Li Z, Wang YA, Ledger W, Edgar DH, Sullivan EA. Clinical outcomes following cryopreservation of blastocysts by vitrification or slow freezing: a population-based cohort study. Hum Reprod. 2014 Dec;29(12):2794-801. doi: 10.1093/humrep/deu246. Epub 2014 Oct 14.
PubMed 25316444Martinez-Rodero I, Gallardo M, Pisaturo V, Scarica C, Conaghan J, Liebermann J, Cuevas-Saiz I. Shorter protocols for vitrification and post-warming dilution of human oocytes and embryos: a narrative review. Reprod Biomed Online. 2025 Aug;51(2):104857. doi: 10.1016/j.rbmo.2025.104857. Epub 2025 Feb 7.
PubMed 40479947Perez-Sanchez M, Pardinas ML, Diez-Juan A, Quinonero A, Dominguez F, Martin A, Vidal C, Beltran D, Mifsud A, Mercader A, Pellicer A, Cobo A, de Los Santos MJ. The effect of vitrification on blastocyst mitochondrial DNA dynamics and gene expression profiles. J Assist Reprod Genet. 2023 Nov;40(11):2577-2589. doi: 10.1007/s10815-023-02952-3. Epub 2023 Oct 6.
PubMed 37801195Rienzi L, Gracia C, Maggiulli R, LaBarbera AR, Kaser DJ, Ubaldi FM, Vanderpoel S, Racowsky C. Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance. Hum Reprod Update. 2017 Mar 1;23(2):139-155. doi: 10.1093/humupd/dmw038.
PubMed 27827818Sciorio R, Tramontano L, Campos G, Greco PF, Mondrone G, Surbone A, Greco E, Talevi R, Pluchino N, Fleming S. Vitrification of human blastocysts for couples undergoing assisted reproduction: an updated review. Front Cell Dev Biol. 2024 May 17;12:1398049. doi: 10.3389/fcell.2024.1398049. eCollection 2024.
PubMed 38827525Sekhon L, Lee JA, Flisser E, Copperman AB, Stein D. Blastocyst vitrification, cryostorage and warming does not affect live birth rate, infant birth weight or timing of delivery. Reprod Biomed Online. 2018 Jul;37(1):33-42. doi: 10.1016/j.rbmo.2018.03.023. Epub 2018 Apr 21.
PubMed 29706285Van Landuyt L, Polyzos NP, De Munck N, Blockeel C, Van de Velde H, Verheyen G. A prospective randomized controlled trial investigating the effect of artificial shrinkage (collapse) on the implantation potential of vitrified blastocysts. Hum Reprod. 2015 Nov;30(11):2509-18. doi: 10.1093/humrep/dev218. Epub 2015 Sep 12.
PubMed 26364080
Study at a glance
From the registry record, last updated by the sponsor on 30 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Validation of Ultra-rapid Blastocyst Vitrification: a Randomized Pilot Study in Oocyte Donation Cycles
- ClinicalTrials.gov ID
- NCT07556601
- Acronym / sponsor ID
- FSD-UFV-2026-04
- Conditions
- Infertility
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Fundacion DexeusUniversity, hospital or other
- Study start
- 1 Jun 2026 (actual)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Mar 2028 (estimated)
- First posted
- 29 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Blastocyst vitrification is standard in assisted reproduction, but clinical data on ultra-rapid vitrification are limited. This pilot study evaluates the safety, feasibility, and preliminary clinical performance of an ultra-rapid blastocyst vitrification protocol compared with the standard approach.
Detailed description
Blastocyst cryopreservation by vitrification is currently the standard approach in assisted reproductive technology, providing high post-warming survival rates and clinical outcomes comparable to those of fresh embryo transfer. Ongoing refinements of vitrification techniques aim to further improve laboratory efficiency and workflow while maintaining biological safety and clinical effectiveness.
Ultra-rapid vitrification protocols have been developed to shorten equilibration times by modifying exposure kinetics to cryoprotectants, while preserving the fundamental biophysical principles of vitrification. Although ultra-rapid warming protocols are well established, clinical data specifically evaluating ultra-rapid vitrification of blastocysts remain limited.
Moreover, ultra-rapid vitrification requires mechanical collapse of the blastocyst before cooling, introducing an additional embryological manipulation with potential biological implications that warrant careful clinical validation. In this context, the present pilot study aims to evaluate the safety, feasibility, and preliminary clinical performance of ultra-rapid blastocyst vitrification compared with the standard vitrification protocol, prior to broader clinical implementation.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standard Vitrification Protocol | Active comparator | Other: Standard VitrificationThe standard vitrification protocol corresponds to the routine clinical practice of the laboratory and consists of the following steps: 1. Equilibration step: Blastocysts are equilibrated in Equilibration Solution (ES) for 10-12 minutes at room temperature. 2. Vitrification solution exposure: Blastocysts are then transferred to Vitrification Solution (VS) for a maximum exposure time of 90 seconds. 3. Loading: The blastocyst is loaded onto a Cryotop device (Kitazato). 4. Vitrification: The Cryotop is plunged directly into liquid nitrogen within 1 second of loading to ensure ultra-rapid cooling. 5. Capping: The Cryotop is immediately capped under liquid nitrogen conditions. |
| Ultra-Rapid Vitrification Protocol | Experimental | Other: Ultra-Rapid VitrificationThe ultra-rapid vitrification protocol is identical to the standard protocol in terms of media, devices, and laboratory conditions, with the following modifications: Preparation step - Blastocyst shrinkage: Prior to equilibration, artificial collapse of the blastocyst is performed using a single laser pulse to induce blastocoel shrinkage. The subsequent steps are: 1. Equilibration step: Blastocysts are equilibrated in Equilibration Solution (ES) for 2-4 minutes. Vitrification solution exposure: Transfer to Vitrification Solution (VS) for a maximum of 90 seconds. 3. Loading: Loading of the blastocyst onto a Cryotop device. 4. Vitrification: Immediate plunging of the Cryotop into liquid nitrogen within 1 second. 5. Capping: Immediate capping under liquid nitrogen. |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Recipients of donor oocytes
- Blastocysts suitable for cryopreservation
Key exclusion criteria (2 listed)
- Cycles involving PGT
- Cycles not reaching blastocyst stage.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Standard Vitrification1. Equilibration step: Blastocysts are equilibrated in Equilibration Solution (ES) for 10-12 minutes at room temperature. 2. Vitrification solution exposure: Blastocysts are then transferred to Vitrification Solution (VS) for a maximum exposure time of 90 seconds. 3. Loading: The blastocyst is loaded onto a Cryotop device (Kitazato). 4. Vitrification: The Cryotop is plunged directly into liquid nitrogen within 1 second of loading to ensure ultra-rapid cooling. 5. Capping: The Cryotop is immediately capped under liquid nitrogen conditions. | Other | Standard Vitrification Protocol |
| Ultra-Rapid VitrificationThe ultra-rapid vitrification protocol is identical to the standard protocol in terms of media, devices, and laboratory conditions, with the following modifications: Preparation step - Blastocyst shrinkage: Prior to equilibration, artificial collapse of the blastocyst is performed using a single laser pulse to induce blastocoel shrinkage. The subsequent steps are: 1. Equilibration step: Blastocysts are equilibrated in Equilibration Solution (ES) for 2-4 minutes. 2. Vitrification solution exposure: Transfer to Vitrification Solution (VS) for a maximum of 90 seconds. 3. Loading: Loading of the blastocyst onto a Cryotop device. 4. Vitrification: Immediate plunging of the Cryotop into liquid nitrogen within 1 second. 5. Capping: Immediate capping under liquid nitrogen. | Other | Ultra-Rapid Vitrification Protocol |
Primary outcome
Post-warming survival rate
Time frame: Immediately after warming (within the same laboratory session)
the proportion of vitrified blastocysts that remain morphologically viable after warming, expressed as a percentage of all warmed blastocysts.
Clinical pregnancy rate per transfer (only first transfer will be considered).
Time frame: 6-8 weeks after embryo transfer
defined as the proportion of embryo transfers resulting in a clinical pregnancy, confirmed by the presence of an intrauterine gestational sac on ultrasound. Only the first embryo transfer per patient is included in the analysis.
4 secondary outcomes
Blastocyst re-expansion
Time frame: Within 2 hours after warming
Post-warming blastocyst morphokinetic parameters
Time frame: From embryo warming until embryo transfer (within 2-6 hours post-warming)
Post-warming blastocyst morphological quality
Time frame: From embryo warming until embryo transfer (within 2-6 hours post-warming)
Technical or embryological adverse events.
Time frame: From blastocyst warming until embryo transfer, within the same clinical procedure (up to 6 hours post-warming)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jun 2026.
- Background: PubMed 31973647Boyard J, Reignier A, Chtourou S, Lefebvre T, Barriere P, Freour T. Should artificial shrinkage be performed prior to blastocyst vitrification? A systematic review of the literature and meta-analysis. Hum Fertil (Camb). 2022 Feb;25(1):24-32. doi: 10.1080/14647273.2019.1701205. Epub 2020 Jan 24.
- Background: PubMed 36410446George JS, Keefe KW. Freezer burn or learning curve? Prolonged time since blastocyst vitrification and impact on pregnancy outcomes. Fertil Steril. 2023 Jan;119(1):45-46. doi: 10.1016/j.fertnstert.2022.11.017. Epub 2022 Nov 19. No abstract available.
- Background: PubMed 41686351Gunst J, Joris H, Vynck M, Godderis K, Vercammen M, Roggeman S, van de Vijver A. Validation and clinical study of single-step vitrification combined with single-step warming of human blastocysts. J Assist Reprod Genet. 2026 Mar;43(3):837-850. doi: 10.1007/s10815-025-03790-1. Epub 2026 Feb 13.
- Background: PubMed 35963753Kovacic B, Taborin M, Vlaisavljevic V, Reljic M, Knez J. To collapse or not to collapse blastocysts before vitrification? A matched case-control study on single vitrified-warmed blastocyst transfers. Reprod Biomed Online. 2022 Oct;45(4):669-678. doi: 10.1016/j.rbmo.2022.03.030. Epub 2022 Apr 10.
- Background: PubMed 25316444Li Z, Wang YA, Ledger W, Edgar DH, Sullivan EA. Clinical outcomes following cryopreservation of blastocysts by vitrification or slow freezing: a population-based cohort study. Hum Reprod. 2014 Dec;29(12):2794-801. doi: 10.1093/humrep/deu246. Epub 2014 Oct 14.
- Background: PubMed 40479947Martinez-Rodero I, Gallardo M, Pisaturo V, Scarica C, Conaghan J, Liebermann J, Cuevas-Saiz I. Shorter protocols for vitrification and post-warming dilution of human oocytes and embryos: a narrative review. Reprod Biomed Online. 2025 Aug;51(2):104857. doi: 10.1016/j.rbmo.2025.104857. Epub 2025 Feb 7.
- Background: PubMed 37801195Perez-Sanchez M, Pardinas ML, Diez-Juan A, Quinonero A, Dominguez F, Martin A, Vidal C, Beltran D, Mifsud A, Mercader A, Pellicer A, Cobo A, de Los Santos MJ. The effect of vitrification on blastocyst mitochondrial DNA dynamics and gene expression profiles. J Assist Reprod Genet. 2023 Nov;40(11):2577-2589. doi: 10.1007/s10815-023-02952-3. Epub 2023 Oct 6.
- Background: PubMed 27827818Rienzi L, Gracia C, Maggiulli R, LaBarbera AR, Kaser DJ, Ubaldi FM, Vanderpoel S, Racowsky C. Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance. Hum Reprod Update. 2017 Mar 1;23(2):139-155. doi: 10.1093/humupd/dmw038.
- Background: PubMed 38827525Sciorio R, Tramontano L, Campos G, Greco PF, Mondrone G, Surbone A, Greco E, Talevi R, Pluchino N, Fleming S. Vitrification of human blastocysts for couples undergoing assisted reproduction: an updated review. Front Cell Dev Biol. 2024 May 17;12:1398049. doi: 10.3389/fcell.2024.1398049. eCollection 2024.
- Background: PubMed 29706285Sekhon L, Lee JA, Flisser E, Copperman AB, Stein D. Blastocyst vitrification, cryostorage and warming does not affect live birth rate, infant birth weight or timing of delivery. Reprod Biomed Online. 2018 Jul;37(1):33-42. doi: 10.1016/j.rbmo.2018.03.023. Epub 2018 Apr 21.
- Background: PubMed 26364080Van Landuyt L, Polyzos NP, De Munck N, Blockeel C, Van de Velde H, Verheyen G. A prospective randomized controlled trial investigating the effect of artificial shrinkage (collapse) on the implantation potential of vitrified blastocysts. Hum Reprod. 2015 Nov;30(11):2509-18. doi: 10.1093/humrep/dev218. Epub 2015 Sep 12.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Infertility
RecruitingObservational study
Safety and Efficacy of Corifollitropin Alfa N02 Injection in Elderly Women Undergoing Assisted Reproductive Technology (ART)
Infertility
Active, not recruiting
Automation of the In Vitro Fertilization Laboratory
Infertility, ART
RecruitingObservational study
Inherited Reproductive Disorders
Genetic Disorder, Infertility
RecruitingObservational study
Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy
Acute Ovarian Failure, Infertility
Not yet recruiting
Implementing IVM for Fertility Treatment in Clinical Practice
Infertility
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Standard Vitrification and Ultra-Rapid Vitrification in people with Infertility, run by Fundacion Dexeus at 2 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Monica Parriego, PhD (0034932274700, monpar@dexeus.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Post-warming survival rate (time frame: Immediately after warming (within the same laboratory session)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07556601, which also lists 11 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jun 2026.